{
    "clinical_study": {
        "@rank": "134344", 
        "arm_group": {
            "arm_group_label": "adipose tissue derived stromal cells", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "Mesenchymal stem cells have capability to differentiate into myocardium, vascular\n      endothelial cell, vascular smooth muscle cell and will be useful for heart regeneration.\n      Adipose tissue is relatively enriched with mesenchymal stem cell compared to bone marrow\n      tissue. In this trial, eligible ischemic heart failure patients will be proceeded\n      intracoronary administration of autologous adipose tissue derived stromal cells by cardiac\n      catheterization."
        }, 
        "brief_title": "Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Ischemic Heart Failure", 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Ischemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "The population of the ischemic heart failure patients is enormous in Japan and the only\n      radical treatment for them is heart transplantation: however, the number of giving donor is\n      extremely limited. Mesenchymal stem cells have been capable to differentiate into\n      mesodermal-lineage cells as well as endodermal-lineage cells such as myocardial cell. They\n      reside in the mesenchymal tissues such as bone marrows as well as adipose tissues. The\n      latter tissues are relatively enriched with mesenchymal stem cells compared to bone marrow\n      cells. In this study, the ischemic heart failure patients will undergo intracoronary\n      administration of autologous adipose tissue derived stromal cells through cardiac\n      catheterization."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Heart failure patients occured by prior ischemic event whose ejection fraction must\n             be less than 40%.\n\n        Exclusion Criteria:\n\n          -  Complicated severe other organ disease.\n\n          -  Patient with malignancy.\n\n          -  History of chemotherapy or irradiation within 4 weeks.\n\n          -  Patient with immunodeficiency\n\n          -  Pregnancy or possibility of pregnancy\n\n          -  Candidate who are judged to be not applicable to this study by doctors."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01709279", 
            "org_study_id": "1133"
        }, 
        "intervention": {
            "arm_group_label": "adipose tissue derived stromal cells", 
            "description": "intra-coronary administration of autologous adipose tissue derived stroma cells", 
            "intervention_name": "adipose tissue derived stromal cells dosage", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ischemic heart failure", 
            "Myocardial regeneration", 
            "ADRC"
        ], 
        "lastchanged_date": "October 16, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kanazawa", 
                    "country": "Japan", 
                    "state": "Ishikawa", 
                    "zip": "920-8641"
                }, 
                "name": "Kanazawa University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "all cause harmful events", 
            "safety_issue": "Yes", 
            "time_frame": "6 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01709279"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kanazawa University", 
            "investigator_full_name": "Shuichi Kaneko", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Kanazawa University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kanazawa University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}